On September 5, 2023, Amber Therapeutics (Amber) announced that they acquired Bioinduction Limited (Bioinduction) and its Picostim DyNeuMo neuromodulation therapy platform. Wilson Sonsini advised Amber on intellectual property matters related to the acquisition.

The acquisition supports Amber's strategy to develop intelligent, transformative neuromodulation therapies for patients with functional disorders of the nervous system. Financial details of the deal were not disclosed.

The Wilson Sonsini team that advised Amber on IP matters related to the transaction included Lou Lieto, Ellie Han, and Michael Rizzuto.

For more information, please see Amber's news release. Additional coverage can be found on Fierce Biotech and Medical Device Network.